Plus Therapeutics Approved New CPT Code for REYOBIQ
Plus Therapeutics announced the American Medical Association's, AMA, CPT, Current Procedural Terminology, Editorial Panel approved a new Category III CPT code to track utilization of convection-enhanced delivery, CED, used in the administration of Reyobiq for recurrent glioblastoma, rGBM, and pediatric brain cancer. "The approved Category III CPT code for convection-enhanced delivery of REYOBIQ in recurrent glioblastoma and pediatric brain cancer - the most prevalent malignant tumors of the brain and central nervous system - marks a major step in bringing market access for an innovative treatment targeting an aggressive and deadly disease resistant to conventional treatments. This milestone reflects the culmination of years of REYOBIQ development and represents an important advancement in our path to commercialization and reimbursement. With standardized REYOBIQ clinical use now tracked under the new CPT code, its utilization can be evaluated as a bridge to approval and broad adoption," said Marc Hedrick MD, Plus Therapeutics President and CEO. "We remain focused on making strong clinical progress with REYOBIQ. We are on track to complete enrollment in our Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting to align on pivotal trial design. In addition, we continue to expect first patient enrollment in our Phase 1 pediatric brain cancer trial in 2026."
